Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy.

CONCLUSION: In nearly 500 NSCLC cases the predominant immune cell type that expresses PD-L1 is CD68+ macrophages. The level of PD-L1 in macrophages is significantly associated with the level of PD-L1 in tumor cells and infiltration by CD8+ T cells, suggesting a connection between high PD-L1 and "hot" tumors. In anti-PD-1 axis therapy treated patients, high levels of PD-L1 expression in macrophages is associated with longer overall survival and may be responsible for the predictive effect of the marker. PMID: 31615933 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research